



PRESS RELEASE

Reclassification of series B shares in Moberg Pharma AB (publ)

STOCKHOLM, November 29th, 2019. During November 2019, Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) has, in accordance with the conversion clause in the Company’s articles of association, reclassified 660,843 series B shares into the same number of ordinary shares. The reclassification entails an increase in the number of ordinary shares and a decrease in the number of series B shares, but does not affect the total number of shares or votes in the Company.

Before the reclassification, the total number of shares in Moberg Pharma amounted to 18,853,510, of which 18,192,667 were common shares, 660,843 were series B shares and none were series C shares. Each common share and series B share entitles to one vote. After the reclassification, the total number of shares in Moberg Pharma amounts to 18,853,510, of which 18,853,510 are common shares and none are series B or series C shares. Hence, neither the total number of shares nor votes in the Company has been affected by the reclassification.

At the time of this press release the Company holds 184,746 own ordinary shares.

For additional information, please contact:

Anna Ljung, CEO, phone: +46 707 66 6030, e-mail: anna.ljung@mobergpharma.se

Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: mark.beveridge@mobergpharma.se

About this information

This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the contact persons set out above, 8.30 a.m. CET on November 29th, 2019.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in more than 800 patients is expected in December 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).